Louisiana 2022 Regular Session

Louisiana House Bill HB182

Introduced
2/24/22  
Introduced
2/24/22  
Refer
2/24/22  
Refer
2/24/22  
Refer
3/14/22  
Report Pass
3/23/22  
Report Pass
3/23/22  
Engrossed
3/29/22  
Engrossed
3/29/22  
Refer
4/4/22  
Refer
4/4/22  
Report Pass
4/13/22  
Report Pass
4/13/22  
Enrolled
5/26/22  
Enrolled
5/26/22  
Chaptered
6/10/22  
Chaptered
6/10/22  
Passed
6/10/22  

Caption

Provides relative to third-party administrators

Impact

The implications of HB 182 on state laws include stricter regulations on third-party administrators for health insurance and pharmacy benefit management. The amendments proposed in the bill modify the filing dates for required reports and expand the reasons under which the commissioner can revoke or deny licenses for administrators. This change is expected to improve the overall regulatory environment by addressing issues of misleading information and ensuring compliance with state standards. The updated timelines for report submission will also help in timely monitoring of pharmacy benefit activities.

Summary

House Bill 182 focuses on the regulatory framework surrounding third-party administrators and pharmacy benefit managers in Louisiana. It seeks to amend specific provisions related to reporting requirements, license denial grounds, and transparency concerning rebates. The bill aims to enhance oversight and accountability in the management of pharmacy benefits, ensuring that administrators submit accurate and timely reports reflecting their contractual relationships with health plans and insurers. By introducing clearer guidelines for transparency, the bill intends to protect consumers and ensure fair practices in drug pricing.

Sentiment

The sentiment surrounding HB 182 is generally positive, particularly among consumer advocacy groups and healthcare professionals who view the bill as a necessary reform to improve accountability in healthcare administration. Supporters argue that increased transparency will lead to better health outcomes and reduced cost burdens on consumers. Some concerns were raised regarding the potential impact on administrative burdens, but overall, there appears to be a consensus on the need for enhanced regulatory oversight in the pharmacy benefit sector.

Contention

While there are no significant points of contention reported regarding HB 182, there may be apprehensions from some segments of the industry about increased regulatory oversight. Stakeholders relying on third-party administration services might express concern over the additional reporting requirements and potential penalties for non-compliance. However, the bill seems to have gained traction without major opposition, indicating a desire among legislators to prioritize transparency and fair practices in health benefit management.

Companion Bills

No companion bills found.

Similar Bills

No similar bills found.